Drug data last refreshed 11h ago · AI intelligence enriched 1mo ago
TINDAMAX (tinidazole) is an oral nitroimidazole antibiotic approved in 2004 for treating parasitic and protozoal infections. It works by disrupting DNA synthesis in target organisms, making it effective against infections caused by Giardia, Entamoeba, and Trichomonas. The drug is administered as a single-dose or short-course oral tablet regimen.
As LOE approaches, the brand team is likely contracting; focus shifts to maximizing remaining exclusivity and preparing for generic transition.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
"Sexual Health Assessment of TinidaZole Against M. Genitalium (SHAZAM)"
Tinidazole for Recurrent Bacterial Vaginosis: A Pilot Study
NGU: Doxycycline (Plus or Minus Tinidazole) Versus Azithromycin (Plus or Minus Tinidazole)
Treatment of Bacterial Vaginosis With Oral Tinidazole
Treatment of Bacterial Vaginosis (BV) With Tinidazole
Worked on TINDAMAX at Mission Therapeutics? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on TINDAMAX offers limited long-term career opportunity given its LOE approaching lifecycle stage and minimal linked job openings. Roles focus on maximizing remaining branded revenue through managed markets and provider relationships before generic transition.